Loading...
Please wait, while we are loading the content...
Similar Documents
How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation
| Content Provider | Scilit |
|---|---|
| Author | Einsele, Hermann Ljungman, Per T. Boeckh, Michael J. |
| Copyright Year | 2020 |
| Description | Cytomegalovirus (CMV) reactivation remains one of the most common and life-threatening infectious complications following allogeneic hematopoietic stem cell transplantation, despite novel diagnostic technologies, several novel prophylactic agents, and further improvements in preemptive therapy and treatment of established CMV disease. Treatment decisions for CMV reactivation are becoming increasingly difficult and must take into account whether the patient has received antiviral prophylaxis, the patient’s individual risk profile for CMV disease, CMV-specific T-cell reconstitution, CMV viral load, and the potential drug resistance detected at the time of initiation of antiviral therapy. Thus, we increasingly use personalized treatment strategies for the recipient of an allograft with CMV reactivation based on prior use of anti-CMV prophylaxis, viral load, the assessment of CMV-specific T-cell immunity, and the molecular assessment of resistance to antiviral drugs. |
| Related Links | https://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2019000956/1720001/blood.2019000956.pdf |
| Ending Page | 1629 |
| Page Count | 11 |
| Starting Page | 1619 |
| DOI | 10.1182/blood.2019000956 |
| Journal | Blood |
| Issue Number | 19 |
| Volume Number | 135 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2020-05-07 |
| Access Restriction | Open |
| Subject Keyword | Research and Experimental Medicine Treatment Hematopoietic Prophylaxis Antiviral Viral Load Stem Transplantation Allogeneic Cmv Reactivation Journal: Blood (Vol- 131, Issue- 19) |
| Content Type | Text |
| Resource Type | Article |